Pamela Russell

Last updated

Pamela Russell
AM FAHMS
Personal details
DiedFebruary 2022
NationalityAustralian
Occupation Immunologist, medical researcher

Pamela J. Russell (died February 2022) [1] was an Australian academic researcher of immunology, bladder and prostate research. [2] Russell was awarded Membership of the Order of Australia (AM) for her research on prostate and bladder cancer in 2003. [3]

Contents

Biography

Russell was Emeritus Professor at the Institute of Health and Biomedical Innovation, Queensland University of Technology, based at the Translational Research Institute (Australia) [4] and adjunct professor, Centre for Advanced Imaging, University of Queensland. [5]

Education and training

Russell trained in immunology at Walter & Eliza Hall Institute, where she obtained an MSc with Sir Macfarlane Burnet. Subsequently, Russell completed a PhD with Sir Gustav Nossal, on studies of autoimmune diseases. [6] [7]

Russell's postdoctoral training was at the John Curtin School of Medical Research, Canberra, and then she moved to Sydney to take up a postdoctoral position at The Kolling Institute of Medical Research. [4]

Russell joined the APCRC – Q in 2009. [8]

Research

Russell's early work in Immunology on Systemic Lupus Erythematosus (SLE) showed that the immunosuppressive drug, cyclophosphamide, could be successfully used to treat animals with this disease, leading to its use in patients with SLE. Early work WEHI showed that T cells could kill cancer cells. [9] Further studies of autoimmunity were performed by Russell's group at the Kolling Institute specifically SLE. [10] but also some related work in rheumatoid arthritis and in ankylosing spondylitis and its association with HLA-B27. [11] [12]

Russell's focus of the work at the Kolling Institute was on autoimmunity, specifically Systemic Lupus Erythematosus (SLE), [13] but also some related work in rheumatoid arthritis and in ankylosing spondylitis and its association with HLAB27. [14] [15]

In 1984, Russell changed her research focus to cancer and, with Dr. Derek Raghavan, established the Urological Cancer Research Centre at Royal Prince Alfred Hospital/University of Sydney. Russell then directed the Oncology Research Centre (ORC), Prince of Wales Hospital from 1992 to 2010, as conjoint Professor of Medicine, University of New South Wales (UNSW).

Russell then moved to the Translational Research Institute and the Australian Prostate Cancer Research Centre in Queensland in 2012. [16] [17]

Awards

Selected Publications

Related Research Articles

<span class="mw-page-title-main">Autoimmunity</span> Immune response against an organisms own healthy cells

In immunology, autoimmunity is the system of immune responses of an organism against its own healthy cells, tissues and other normal body constituents. Any disease resulting from this type of immune response is termed an "autoimmune disease". Prominent examples include celiac disease, diabetes mellitus type 1, Henoch–Schönlein purpura, systemic lupus erythematosus, Sjögren syndrome, eosinophilic granulomatosis with polyangiitis, Hashimoto's thyroiditis, Graves' disease, idiopathic thrombocytopenic purpura, Addison's disease, rheumatoid arthritis, ankylosing spondylitis, polymyositis, dermatomyositis, and multiple sclerosis. Autoimmune diseases are very often treated with steroids.

<span class="mw-page-title-main">Methotrexate</span> Chemotherapy and immunosuppressant medication

Methotrexate, formerly known as amethopterin, is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Types of autoimmune diseases it is used for include psoriasis, rheumatoid arthritis, and Crohn's disease. It can be given by mouth or by injection.

<span class="mw-page-title-main">Ankylosing spondylitis</span> Type of arthritis of the spine

Ankylosing spondylitis (AS) is a type of arthritis from the disease spectrum of axial spondyloarthritis. It is characterized by long-term inflammation of the joints of the spine, typically where the spine joins the pelvis. With AS, eye and bowel problems—as well as back pain—may occur. Joint mobility in the affected areas sometimes worsens over time. Ankylosing spondylitis is believed to involve a combination of genetic and environmental factors. More than 90% of people affected in the UK have a specific human leukocyte antigen known as the HLA-B27 antigen. The underlying mechanism is believed to be autoimmune or autoinflammatory. Diagnosis is based on symptoms with support from medical imaging and blood tests. AS is a type of seronegative spondyloarthropathy, meaning that tests show no presence of rheumatoid factor (RF) antibodies.

<span class="mw-page-title-main">HLA-B27</span> Type of antigen

Human leukocyte antigen (HLA) B27 is a class I surface molecule encoded by the B locus in the major histocompatibility complex (MHC) on chromosome 6 and presents antigenic peptides to T cells. HLA-B27 is strongly associated with ankylosing spondylitis and other associated inflammatory diseases, such as psoriatic arthritis, inflammatory bowel disease, and reactive arthritis.

Spondyloarthritis (SpA), also known as spondyloarthropathy, is a collection of clinical syndromes that are connected by genetic predisposition and clinical manifestations. The best-known clinical subtypes are enteropathic arthritis (EA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and reactive arthritis (ReA). Spondyloarthritis typically presents with inflammatory back pain and asymmetrical arthritis, primarily affecting the lower limbs, and enthesitis, inflammation at bone-adhering ligaments, tendons, or joint capsules.

<span class="mw-page-title-main">Uveitis</span> Inflammation of the uvea of the eye

Uveitis is inflammation of the uvea, the pigmented layer of the eye between the inner retina and the outer fibrous layer composed of the sclera and cornea. The uvea consists of the middle layer of pigmented vascular structures of the eye and includes the iris, ciliary body, and choroid. Uveitis is described anatomically, by the part of the eye affected, as anterior, intermediate or posterior, or panuveitic if all parts are involved. Anterior uveitis (iridocyclitis) is the most common, with the incidence of uveitis overall affecting approximately 1:4500, most commonly those between the ages of 20–60. Symptoms include eye pain, eye redness, floaters and blurred vision, and ophthalmic examination may show dilated ciliary blood vessels and the presence of cells in the anterior chamber. Uveitis may arise spontaneously, have a genetic component, or be associated with an autoimmune disease or infection. While the eye is a relatively protected environment, its immune mechanisms may be overcome resulting in inflammation and tissue destruction associated with T-cell activation.

<span class="mw-page-title-main">HLA-B</span> Protein-coding gene in the species Homo sapiens

HLA-B is a human gene that provides instructions for making a protein that plays a critical role in the immune system. HLA-B is part of a family of genes called the human leukocyte antigen (HLA) complex. The HLA complex helps the immune system distinguish the body's own proteins from proteins made by foreign invaders such as viruses and bacteria.

<span class="mw-page-title-main">Leflunomide</span> Chemical compound

Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug (DMARD), used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase.

Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).

<span class="mw-page-title-main">HLA-A24</span> Human leukocyte antigen serotype

HLA-A24 (A24) is a human leukocyte antigen serotype within HLA-A serotype group. The serotype is determined by the antibody recognition of α24 subset of HLA-A α-chains. For A24, the alpha, "A", chain are encoded by the HLA-A*24 allele group and the β-chain are encoded by B2M locus. This group currently is dominated by A*2402. A24 and A*24 are almost synonymous in meaning. A24 is a split antigen of the broad antigen HLA-A9 and it is a sister serotype of HLA-A23.

<span class="mw-page-title-main">PDCD1LG2</span> Protein-coding gene in the species Homo sapiens

Programmed cell death 1 ligand 2 is a protein that in humans is encoded by the PDCD1LG2 gene. PDCD1LG2 has also been designated as CD273. PDCD1LG2 is an immune checkpoint receptor ligand which plays a role in negative regulation of the adaptive immune response. PD-L2 is one of two known ligands for Programmed cell death protein 1 (PD-1).

<span class="mw-page-title-main">Deoxyribonuclease gamma</span> Protein-coding gene in the species Homo sapiens

Deoxyribonuclease gamma is an enzyme that in humans is encoded by the DNASE1L3 gene. This gene's is located on chromosome 3's "p arm", i.e., short arm, between region 1, band 4, sub-band 3 and region 2, band 1, sub-band 1

<span class="mw-page-title-main">Complement 2 deficiency</span> Medical condition

Complement 2 deficiency is a type of complement deficiency caused by any one of several different alterations in the structure of complement component 2.

<span class="mw-page-title-main">Anti-dsDNA antibodies</span> Group of anti-nuclear antibodies

Anti-double stranded DNA (Anti-dsDNA) antibodies are a group of anti-nuclear antibodies (ANA) the target antigen of which is double stranded DNA. Blood tests such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence are routinely performed to detect anti-dsDNA antibodies in diagnostic laboratories. They are highly diagnostic of systemic lupus erythematosus (SLE) and are implicated in the pathogenesis of lupus nephritis.

James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.

Fibrous ankylosis is a condition that affects fibrous connective tissue causing a limited range of movement.

<span class="mw-page-title-main">Secukinumab</span> Monoclonal antibody against IL-17

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

Alan Martin Ebringer is an Australian immunologist, professor at King's College London. He is also an Honorary Consultant Rheumatologist in the Middlesex Hospital, now part of the UCH School of Medicine. He is known for his research in the field of autoimmune disease.

<span class="mw-page-title-main">Axial spondyloarthritis</span> Medical condition

Axial spondyloarthritis is a chronic, immune-mediated disease predominantly affecting the axial skeleton. The term itself is an umbrella term characterizing a diverse disease family united by shared clinical and genetic features, such as the involvement of the axial skeleton. The 2009 introduced term axial spondyloarthritis is a preferred term nowadays and substitutes the old term ankylosing spondylitis.

<span class="mw-page-title-main">Interleukin 40</span> Mammalian cytokine

Interleukin 40 (IL-40), also known with other name C17orf99, is a protein belonging to a group of cytokines called interleukins. It is encoded by a gene that does not belong to any cytokine superfamily. This cytokine is produced primarily by human expression tissues such as bone marrow and fetal liver, and its expression can be also induced in peripheral B cells after activation. IL-40 is involved in immunoglobulin A (IgA) production, and plays an important role in humoral immune responses and B cell homeostasis and development.

References

  1. ↑ "In Memory of Emeritus Professor Pamela Russell AM". Prostate Cancer Foundation of Australia. 3 March 2022. Archived from the original on 19 May 2024. Retrieved 20 July 2024.
  2. ↑ "Pamela Russell". www.qut.edu.au. Archived from the original on 18 April 2019. Retrieved 12 February 2019.
  3. ↑ "2003 Australia Day Honours List: AC, AO, AM". www.theage.com.au. 26 January 2003. Archived from the original on 24 May 2021. Retrieved 12 February 2019.
  4. 1 2 "Pamela Russell". www.tri.edu.au. Retrieved 12 February 2019.
  5. 1 2 "Pamela Russell — Australian Prostate Cancer Research Centre - Queensland". www.australianprostatecentre.org. Archived from the original on 1 August 2017. Retrieved 6 March 2018.
  6. ↑ "Pamela Russell — Australian Prostate Cancer Research Centre - Queensland". www.australianprostatecentre.org. Archived from the original on 1 August 2017. Retrieved 24 July 2024.
  7. ↑ "Pamela Russell | Translational Research Institute". www.tri.edu.au. Archived from the original on 2 May 2019. Retrieved 24 July 2024.
  8. ↑ "Professor Pamela Russell — Prostate Cancer Collaborative Research Alliance". www.aus-canprostatealliance.org. Archived from the original on 14 August 2014. Retrieved 14 August 2014.
  9. ↑ Cameron, Fiona H.; Russell, Pamela J.; Easter, Joan F.; Wakefield, Denis; March, Lyn (1987). "Failure Of klebsiella pneumoniae antibodies to cross-react with peripheral blood mononuclear cells from patients with ankylosing spondylitis". Arthritis & Rheumatism. 30 (3): 300–305. doi:10.1002/art.1780300309. PMID   3551965.
  10. ↑ Cameron, F.; Russell, P.; Sullivan, J.; Geczy, A. (1983). "Is a Klebsiella plasmid involved in the aetiology of ankylosing spondylitis in HLA-b27-positive individuals?". Molecular Immunology. 20 (5): 563–566. doi:10.1016/0161-5890(83)90095-0. PMID   6348514.
  11. ↑ "Cell Surface Prostate Cancer Antigen for Diagnosis" . Retrieved 22 May 2019.
  12. ↑ "Minomic secures key patent in the United States and China". 5 September 2018. Archived from the original on 19 September 2020. Retrieved 22 May 2019.
  13. ↑ Russell, Pamela J., and Alfred D. Steinberg. "Studies of peritoneal macrophage function in mice with systemic lupus erythematosus: Depressed phagocytosis of opsonized sheep erythrocytes in vitro." Clinical immunology and immunopathology 27, no. 3 (1983): 387-402.
  14. ↑ Cameron, Fiona H., Pamela J. Russell, Joan F. Easter, Denis Wakefield, and Lyn March. "Failure Of klebsiella pneumoniae antibodies to cross‐react with peripheral blood mononuclear cells from patients with ankylosing spondylitis." Arthritis & Rheumatism 30, no. 3 (1987): 300-305.
  15. ↑ Cameron, Fiona H., Pamela J. Russell, John Sullivan, and Andrew F. Geczy. "Is a Klebsiella plasmid involved in the aetiology of ankylosing spondylitis in HLA-B27-positive individuals?." Molecular Immunology 20, no. 5 (1983): 563-566.
  16. ↑ "Vale Emeritus Professor Pamela Russell AM FAHMS". Australian Academy of Health and Medical Sciences. 10 March 2022. Retrieved 12 March 2022.
  17. 1 2 "Remembering The Late Professor Pamela Russell AM". Funding Cancer Research | Cure Cancer. 2 March 2022. Retrieved 12 March 2022.
  18. ↑ "APCRC - Q Researcher Wins PCFA Award". Archived from the original on 29 September 2020. Retrieved 12 February 2019.
  19. ↑ "Fellowship of the Australian Academy of Health and Medical Sciences October 2015" (PDF). Archived from the original (PDF) on 25 June 2021. Retrieved 12 February 2019.
  20. ↑ "Pam Russell AM Alumni Excellence Award Health Winner". Archived from the original on 9 November 2019. Retrieved 12 February 2019.
  21. ↑ Singh, Preetiner Pal; Joshi, Swapna; Russell, Pamela J.; Verma, Nirupama D.; Wang, Xiaochun; Khatri, Aparajita (15 June 2011). "Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer". Clinical Cancer Research. 17 (12): 4006–4018. doi:10.1158/1078-0432.CCR-11-0248. ISSN   1557-3265. PMID   21531822. Archived from the original on 27 July 2024. Retrieved 26 December 2024.
  22. ↑ Hung, Tzong-Tyng; Chan, Jeffrey; Russell, Pamela J.; Power, Carl A. (2011). "Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model". PLOS ONE. 6 (5): e19389. Bibcode:2011PLoSO...619389H. doi: 10.1371/journal.pone.0019389 . ISSN   1932-6203. PMC   3095598 . PMID   21603655.
  23. ↑ Tang, Catherine; Russell, Pamela J.; Martiniello-Wilks, Rosetta; Rasko, John E. J.; Khatri, Aparajita (September 2010). "Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?". Stem Cells. 28 (9): 1686–1702. doi:10.1002/stem.473. ISSN   1549-4918. PMC   2996089 . PMID   20629172.
  24. ↑ Khatri, Aparajita; Husaini, Yasmin; Ow, Kim; Chapman, Jane; Russell, Pamela J. (1 April 2009). "Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines". Clinical Cancer Research. 15 (7): 2323–2334. doi:10.1158/1078-0432.CCR-08-2039. ISSN   1078-0432. PMID   19318483. Archived from the original on 26 July 2024. Retrieved 26 December 2024.
  25. ↑ Li, Yong; Song, Emma; Abbas Rizvi, Syed M.; Power, Carl A.; Beretov, Julia; Raja, Chand; Cozzi, Paul J.; Morgenstern, Alfred; Apostolidis, Christos; Allen, Barry J.; Russell, Pamela J. (1 February 2009). "Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates". Clinical Cancer Research. 15 (3): 865–875. doi:10.1158/1078-0432.CCR-08-1203. ISSN   1078-0432. PMID   19188157. Archived from the original on 26 July 2024. Retrieved 26 December 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.